Insider · CIK 0001623108

Frenkel Ran

Reports to the SEC for 1 company · NEWTON, MA

sec.gov

Transactions

Companies

Filings

CIK

0001623108

Forms 4 and 5

Insider transactions

34 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2022-02-28	KPTIKaryopharm Therapeutics Inc.A Award	EVP, Chief Dev. Officer	AAward	+68.3K sh	—	—	169,953
2022-02-28	KPTIKaryopharm Therapeutics Inc.S Sale	EVP, Chief Dev. Officer	SSale	−1,663 sh	$10.24	−$17K	168,290
2022-02-28	KPTIKaryopharm Therapeutics Inc. · Stock Option (right to buy)A Award	EVP, Chief Dev. Officer	AAward	+90K sh	—	—	90,000
2022-02-17	KPTIKaryopharm Therapeutics Inc.S Sale	EVP, Chief Dev. Officer	SSale	−2,929 sh	$12.12	−$35.5K	101,703
2022-02-07	KPTIKaryopharm Therapeutics Inc.S Sale	EVP, Chief Dev. Officer	SSale	−1,991 sh	$9.86	−$19.6K	104,632
2021-02-25	KPTIKaryopharm Therapeutics Inc.A Award	EVP, Chief Dev. Officer	AAward	+22K sh	—	—	104,439
2021-02-25	KPTIKaryopharm Therapeutics Inc. · Stock Option (right to buy)A Award	EVP, Chief Dev. Officer	AAward	+60K sh	—	—	59,968
2021-02-18	KPTIKaryopharm Therapeutics Inc.S Sale	EVP, Chief Dev. Officer	SSale	−2,887 sh	$14.83	−$42.8K	46,126
2021-02-15	KPTIKaryopharm Therapeutics Inc.M Exercise/Conversion	EVP, Chief Dev. Officer	MExercise/Conversion	+9,675 sh	—	—	49,013
2021-02-15	KPTIKaryopharm Therapeutics Inc. · Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Dev. Officer	MExercise/Conversion	−9,675 sh	—	—	19,350
2021-02-11	KPTIKaryopharm Therapeutics Inc.S Sale	EVP, Chief Dev. Officer	SSale	−2,046 sh	$15.52	−$31.8K	39,338
2021-02-05	KPTIKaryopharm Therapeutics Inc.M Exercise/Conversion	EVP, Chief Dev. Officer	MExercise/Conversion	+5,650 sh	—	—	41,384
2021-02-05	KPTIKaryopharm Therapeutics Inc. · Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Dev. Officer	MExercise/Conversion	−5,650 sh	—	—	16,950
2020-05-07	KPTIKaryopharm Therapeutics Inc.S Sale	EVP, Chief Dev. Officer	SSale	−1,974 sh	$20.00	−$39.5K	35,088
2020-02-19	KPTIKaryopharm Therapeutics Inc.S Sale	EVP, Chief Dev. Officer	SSale	−2,975 sh	$16.48	−$49K	36,066
2020-02-15	KPTIKaryopharm Therapeutics Inc.M Exercise/Conversion	EVP, Chief Dev. Officer	MExercise/Conversion	+9,675 sh	—	—	39,041
2020-02-15	KPTIKaryopharm Therapeutics Inc. · Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Dev. Officer	MExercise/Conversion	−9,675 sh	—	—	29,025
2020-02-05	KPTIKaryopharm Therapeutics Inc. · Stock Option (right to buy)A Award	EVP, Chief Dev. Officer	AAward	+60.6K sh	—	—	60,600
2020-02-05	KPTIKaryopharm Therapeutics Inc. · Restricted Stock UnitsA Award	EVP, Chief Dev. Officer	AAward	+22.6K sh	—	—	22,600
2019-02-15	KPTIKaryopharm Therapeutics Inc. · Stock Option (right to buy)A Award	EVP, Chief Dev. Officer	AAward	+103K sh	—	—	102,800
2019-02-15	KPTIKaryopharm Therapeutics Inc. · Restricted Stock UnitsA Award	EVP, Chief Dev. Officer	AAward	+38.7K sh	—	—	38,700
2018-01-24	KPTIKaryopharm Therapeutics Inc. · Stock Option (right to buy)A Award	EVP, Chief Dev. Officer	AAward	+60K sh	—	—	60,000
2017-11-07	KPTIKaryopharm Therapeutics Inc.S Sale	EVP, Chief Dev. Officer	SSale	−4,958 sh	$11.25	−$55.8K	24,733
2017-11-05	KPTIKaryopharm Therapeutics Inc.M Exercise/Conversion	EVP, Chief Dev. Officer	MExercise/Conversion	+15K sh	—	—	29,691
2017-11-05	KPTIKaryopharm Therapeutics Inc. · Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Dev. Officer	MExercise/Conversion	−15K sh	—	—	0
2017-01-20	KPTIKaryopharm Therapeutics Inc. · Stock Option (right to buy)A Award	EVP, Chief Dev. Officer	AAward	+100K sh	—	—	100,000
2016-11-14	KPTIKaryopharm Therapeutics Inc.S Sale	EVP, Chief Dev. Officer	SSale	−3,309 sh	$10.06	−$33.3K	14,691
2016-11-05	KPTIKaryopharm Therapeutics Inc.M Exercise/Conversion	EVP, Chief Dev. Officer	MExercise/Conversion	+15K sh	—	—	18,000
2016-11-05	KPTIKaryopharm Therapeutics Inc. · Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Dev. Officer	MExercise/Conversion	−15K sh	—	—	15,000
2016-01-15	KPTIKaryopharm Therapeutics Inc. · Stock Option (right to buy)A Award	EVP, Chief Dev. Officer	AAward	+75K sh	—	—	75,000
2015-11-05	KPTIKaryopharm Therapeutics Inc. · Restricted Stock UnitsA Award	EVP, Chief Dev. Officer	AAward	+30K sh	—	—	30,000
2015-04-07	KPTIKaryopharm Therapeutics Inc.P Purchase	EVP, Chief Dev. Officer	PPurchase	+2,000 sh	$33.00	+$66K	3,000
2015-04-06	KPTIKaryopharm Therapeutics Inc.P Purchase	EVP, Chief Dev. Officer	PPurchase	+1,000 sh	$29.43	+$29.4K	1,000
2014-11-19	KPTIKaryopharm Therapeutics Inc. · Incentive Stock Option (right to buy)A Award	EVP, Chief Dev. Officer	AAward	+160K sh	—	—	160,000

Recent filings

Accepted (ET)
Mar 24
Frenkel Ran0001209191-22-014629
SEC(opens sec.gov)
Feb 224
Frenkel Ran0001209191-22-011643
SEC(opens sec.gov)
Feb 94
Frenkel Ran0001209191-22-008128
SEC(opens sec.gov)
Mar 14
Frenkel Ran0001209191-21-015484
SEC(opens sec.gov)
Feb 224
Frenkel Ran0001209191-21-012967
SEC(opens sec.gov)
Feb 174
Frenkel Ran0001209191-21-011490
SEC(opens sec.gov)
Feb 94
Frenkel Ran0001209191-21-009079
SEC(opens sec.gov)
May 114
Frenkel Ran0001209191-20-028271
SEC(opens sec.gov)
Feb 214
Frenkel Ran0001209191-20-011696
SEC(opens sec.gov)
Feb 194
Frenkel Ran0001209191-20-010756
SEC(opens sec.gov)
Feb 74
Frenkel Ran0001209191-20-007510
SEC(opens sec.gov)
Feb 194
Frenkel Ran0001209191-19-011082
SEC(opens sec.gov)

Companies

Karyopharm Therapeutics Inc.EVP, Chief Dev. OfficerKPTI

Address

C/O KARYOPHARM THERAPEUTICS, INC, 85 WELLS AVENUE

NEWTON, MA, 02459